Business Context and Reporting Period
Company: CalciMedica, Inc. (CALC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: CalciMedica is a clinical-stage biopharmaceutical company developing therapeutics for inflammatory, immunologic, and cardiopulmonary diseases. Its primary product candidates are Auxora (IV CRAC channel inhibitor) and CM5480 (oral CRAC channel inhibitor). The company has no approved products and has never generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(7,652) | $(5,956) | $(2,676) | $(10,998) |
| Operating Expenses | $(4,012) | $(6,621) | $(9,623) | $(13,118) |
| Cash and Cash Equivalents (End of Period) | $18,617 | $5,918 | $18,617 | $5,918 |
| Total Debt (Promissory Note) | $9,200 | $9,700 | $9,200 | $9,700 |
| Warrant Liability | $1,300 | $1,000 | $1,300 | $1,000 |
| Accumulated Deficit | $(192,002) | $(170,762) | $(192,002) | $(170,762) |
Note: The YTD 2026 Net Loss of $(2.7M) is significantly lower than YTD 2025 due to a non-cash gain of $7.2M from changes in the fair value of financial instruments (warrants and promissory notes).
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by 39% in Q2 2026 compared to Q2 2025 ($4.0M vs. $6.6M) and by 27% on a YTD basis ($9.6M vs. $13.1M). This reduction is primarily attributed to decreased preclinical and clinical trial activities related to Auxora and the pause in the KOURAGE trial enrollment.
- Financing Activity: In June 2026, the company completed a PIPE financing raising approximately $15.0 million in gross proceeds. Additionally, the company amended its Loan Agreement with Avenue Venture Opportunities Fund II, extending the interest-only period to September 2027 and the maturity date to September 2029.
- Share Count: Common stock outstanding increased from 15.4 million at December 31, 2025, to 30.7 million at June 30, 2026, due to the PIPE financing and warrant exercises.
- Non-Cash Gains: The company recognized a $7.2 million gain from the change in fair value of financial instruments for the six months ended June 30, 2026, compared to a $2.2 million gain in the same period in 2025.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. While cash balances improved to $18.6 million following the PIPE financing, management believes current resources may not be sufficient to fund operations for one year following the issuance of the financial statements (projected into the second half of 2027).
- Clinical Pipeline:
- Auxora: Enrollment in the KOURAGE Phase 2 trial (Acute Kidney Injury) was paused in January 2026 due to a mortality imbalance. The company has no current plans to resume dosing in this trial. The company is preparing for a potential Phase 2b trial in Acute Pancreatitis (AP) following FDA alignment in July 2026.
- CM5480: An oral CRAC channel inhibitor for pulmonary hypertension. The company expects to submit an IND application in mid-2027.
- Capital Needs: The company will need to obtain substantial additional funding to complete development and commercialization. Failure to raise capital could force the company to delay, reduce, or eliminate development programs.
- Nasdaq Compliance: The company received notices from Nasdaq in March 2026 regarding non-compliance with the Minimum Bid Price Requirement (below $1.00) and Market Value of Listed Securities (below $35M). The company has until September 2026 to regain compliance to avoid delisting.
- Legal Proceedings: A stockholder filed a complaint in April 2025 alleging false representations regarding a $1.5 million investment. The company intends to vigorously defend against these allegations.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion post-PIPE financing and the company's concrete plan for raising additional capital before the second half of 2027.
- Nasdaq Status: Monitor the company's progress in regaining compliance with Nasdaq listing standards (Bid Price and MVLS) by the September 2026 deadlines.
- KOURAGE Trial Status: Confirm the final decision regarding the KOURAGE trial and the timeline for initiating the new Phase 2b trial in Acute Pancreatitis.
- Debt Covenants: Review the amended Loan Agreement terms, specifically the conversion features and covenants that may restrict future financing or operations.
- Dilution Impact: Assess the impact of the recent PIPE financing and outstanding warrants (Series A and B pending stockholder approval) on existing shareholder equity.